e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Pulmonary hypertension: promising small molecules
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients
Beatriz Ballester (Burjassot (Valencia), Spain), Beatriz Ballester, Javier Milara, Anselm Morell, Sonia Contreras, Adela Serrano, Sonia González, Julio Cortijo
Source:
International Congress 2015 – Pulmonary hypertension: promising small molecules
Session:
Pulmonary hypertension: promising small molecules
Session type:
Poster Discussion
Number:
4902
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Beatriz Ballester (Burjassot (Valencia), Spain), Beatriz Ballester, Javier Milara, Anselm Morell, Sonia Contreras, Adela Serrano, Sonia González, Julio Cortijo. Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients. Eur Respir J 2015; 46: Suppl. 59, 4902
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir Mon 2012; 57: 148-160
Year: 2012
Pulmonary hypertension in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Accelerated ageing in idiopathic pulmonary fibrosis and pulmonary hypertension
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension in idiopathic pulmonary fibrosis: Utility of HRCT
Source: International Congress 2014 – COPD and PAH related imaging
Year: 2014
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Source: Eur Respir J 2007; 30: 715-721
Year: 2007
Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
Role of midkine in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension
Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017
Year: 2018
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
Source: International Congress 2014 – ILDs 4
Year: 2014
Angiogenesis in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Role of IL-11 in vascular function of pulmonary fibrosis patients
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
The contributing factors to mean pulmonary artery pressure in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Latest insights into chronic care
Year: 2016
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Source: Eur Respir J 2005; 26: 586-593
Year: 2005
Arterial stiffness and endothelial dysfunction in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept